Using T cell engineering plus triple checkpoint blockade to enhance the efficacy of adoptive immunotherapy in ovarian cancer

Bookmark and Share
Published: 15 Apr 2019
Views: 633
Rating:
Save
Dr Kristin Anderson - Fred Hutchinson Cancer Research Center, Seattle, USA

Dr Kristin Anderson speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about a study looking at using T cell engineering plus triple checkpoint blockade to enhance the efficacy of adoptive immunotherapy in ovarian cancer.

Dr Anderson explains that finding an immunotherapeutic approach for treating ovarian cancer is very important as most treatments to date work only in particular subsets of patients, with immunotherapy having the potential to work in all patients.

She reports that they found the need to use three different checkpoint blockade antibodies together in order to reinvigorate the T cells.